Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Abstract Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	hypogonadism hypopituitarism neuroendocrine tumours radioisotopes receptor somatostatin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/023c9ccd95dd41eba7390ebfa9e2d272
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:023c9ccd95dd41eba7390ebfa9e2d272
record_format	dspace
spelling	oai:doaj.org-article:023c9ccd95dd41eba7390ebfa9e2d2722021-12-01T04:49:15ZPituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours2045-763410.1002/cam4.4345https://doaj.org/article/023c9ccd95dd41eba7390ebfa9e2d2722021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4345https://doaj.org/toc/2045-7634Abstract Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim was to assess the prevalence of clinically significant hypopituitarism a minimum of 2 years following radioisotope therapy for metastatic NET. This was a multicentre study (Australia and New Zealand). Sixty‐six patients with unresectable NETs were included–34 had received PRRT and 32 comparison patients. Median follow‐up after PRRT was 68 months. Male hypogonadism was the most common hormonal abnormality (16 of 38 men [42%]) from the total cohort. Of these, seven men had primary hypogonadism (five from PRRT group) and nine had secondary hypogonadism (six in PRRT group). There was no difference in either male hypogonadism or other hormonal dysfunction between patients who had received PRRT and those that had not. Patients who have received PRRT out to 68 months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life.Marianne S. ElstonAmanda LoveDev KevatRichard CarrollZhen Rong SiowSharon PattisonVeronica BoyleEva SegelovAndrew H. StricklandDavid WyldRichard GauciKim KennedyDavid Ransomthe Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)Wileyarticlehypogonadismhypopituitarismneuroendocrine tumoursradioisotopesreceptorsomatostatinNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8405-8411 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hypogonadism hypopituitarism neuroendocrine tumours radioisotopes receptor somatostatin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hypogonadism hypopituitarism neuroendocrine tumours radioisotopes receptor somatostatin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marianne S. Elston Amanda Love Dev Kevat Richard Carroll Zhen Rong Siow Sharon Pattison Veronica Boyle Eva Segelov Andrew H. Strickland David Wyld Richard Gauci Kim Kennedy David Ransom the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
description	Abstract Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim was to assess the prevalence of clinically significant hypopituitarism a minimum of 2 years following radioisotope therapy for metastatic NET. This was a multicentre study (Australia and New Zealand). Sixty‐six patients with unresectable NETs were included–34 had received PRRT and 32 comparison patients. Median follow‐up after PRRT was 68 months. Male hypogonadism was the most common hormonal abnormality (16 of 38 men [42%]) from the total cohort. Of these, seven men had primary hypogonadism (five from PRRT group) and nine had secondary hypogonadism (six in PRRT group). There was no difference in either male hypogonadism or other hormonal dysfunction between patients who had received PRRT and those that had not. Patients who have received PRRT out to 68 months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life.
format	article
author	Marianne S. Elston Amanda Love Dev Kevat Richard Carroll Zhen Rong Siow Sharon Pattison Veronica Boyle Eva Segelov Andrew H. Strickland David Wyld Richard Gauci Kim Kennedy David Ransom the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)
author_facet	Marianne S. Elston Amanda Love Dev Kevat Richard Carroll Zhen Rong Siow Sharon Pattison Veronica Boyle Eva Segelov Andrew H. Strickland David Wyld Richard Gauci Kim Kennedy David Ransom the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)
author_sort	Marianne S. Elston
title	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
title_short	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
title_full	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
title_fullStr	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
title_full_unstemmed	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
title_sort	pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/023c9ccd95dd41eba7390ebfa9e2d272
work_keys_str_mv	AT marianneselston pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT amandalove pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT devkevat pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT richardcarroll pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT zhenrongsiow pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT sharonpattison pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT veronicaboyle pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT evasegelov pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT andrewhstrickland pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT davidwyld pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT richardgauci pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT kimkennedy pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT davidransom pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours AT thecommonwealthneuroendocrinetumourcollaborationcommnets pituitaryfunctionfollowingpeptidereceptorradionuclidetherapyforneuroendocrinetumours
_version_	1718405704277032960

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Ejemplares similares